论文部分内容阅读
目的:系统评价本实验室表达HIV-1B亚型gp160的腺病毒载体疫苗(Ad5-HIV gp160)在小鼠体内的免疫效果。为之后进行的恒河猴药效学提供研究基础,为申报Ⅰ期临床试验提供资料支持和质量检定方法。方法:Ad5-HIV gp160以不同剂量分别免疫小鼠,采用ELISPOT法和ELISA法检测免疫小鼠体内特异性细胞免疫反应和体液免疫反应。结果:各剂量组小鼠均可诱导出较高水平的细胞免疫反应和体液免疫反应。结论:疫苗的质量研究显示基因插入表达正常,Ad5-HIV gp160疫苗剂量为2×108 VP/只时能够在小鼠体内激发出高水平的细胞免疫反应和体液免疫反应。
OBJECTIVE: To systematically evaluate the immunological effects of Ad5-HIV gp160 in vivo in mice expressing HIV-1B subtype gp160 in our laboratory. Provide the basis for the research on the pharmacodynamics of rhesus monkeys afterwards and provide information support and quality test methods for declaring phase I clinical trials. Methods: Ad5-HIV gp160 mice were immunized with different doses respectively. The specific cellular and humoral immune responses in immunized mice were detected by ELISPOT and ELISA. Results: The mice in each dose group could induce a higher level of cellular and humoral immune responses. CONCLUSIONS: The vaccine quality studies showed normal insertion of the gene and the Ad5-HIV gp160 vaccine dose of 2 × 10 8 VP / mouse was able to elicit high levels of cellular and humoral immune responses in mice.